Natera launches Zenith Genomics — its next-generation whole-genome sequencing test for faster rare disease diagnosis. GeneDx shares drop 8% as competition intensifies in the rare-disease market, which carries a $1 trillion economic burden.
French biotech company Abivax strongly rejects media claims that it gave AstraZeneca secret access to its data for a possible buyout until March 23, calling the reports "unfounded rumors."
Oppenheimer starts ProQR Therapeutics (PRQR) coverage with Outperform rating and $9 price target, citing RNA editing potential in liver diseases ahead of 2026 data.
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.
